Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study).

Aims: In the ULTRAFLEXI-1 study, we compared basal insulin Glargine 300 U/mL (IGlar U300) and insulin Degludec 100 U/mL (IDeg U100) for time below range <70 mg/dL (TBR<70; 3.9 mmol/L) in two different doses (100% and 75% of the regular dose) when used around spontaneous exercise sessions in adults with type 1 diabetes. Methods: A randomized, single-center, four-period, cross-over trial was performed and in each of the four 2-weeks-periods, participants attended six spontaneous 60 min moderate-intensity evening cycle ergometer exercise sessions. The basal insulin administered on the exercise days were IGlar U300 100% or 75% of the regular dose or IDeg U100 100% or 75%, respectively (morning injection). The primary outcome was the TBR<70 during the 24 h postexercise periods of the six spontaneous exercise sessions in the four trial arms and was analyzed in hierarchical order using the repeated measures linear mixed model. Results: Twenty-five people with type 1 diabetes were enrolled (14 males) with a mean age of 41.4 ± 11.9 years and an HbA1c of 7.5% ± 0.8% (59 ± 9 mmol/mol). The mean ± standard error of mean TBR<70 during the 24 h periods following the exercise sessions was 2.71% ± 0.51% for IGlar U300 (100%) and 4.37% ± 0.69% for IDeg U100 (100%) (P = 0.023) as well as 2.28% ± 0.53% for IGlar U300 and 2.55% ± 0.58% for IDeg U100 when using a 75% dose on exercise days (P = 0.720). Time in glucose range70-180 was the highest in the IDeg U100 (100%) group. Conclusions: TBR<70 within the first 24 h after spontaneous exercise sessions was significantly lower when receiving IGlar U300 compared to IDeg U100 when a regular basal dose was administered.

[1]  J. Hawley,et al.  The effect of morning vs evening exercise training on glycaemic control and serum metabolites in overweight/obese men: a randomised trial , 2021, Diabetologia.

[2]  Lawrence A Leiter,et al.  Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial , 2020, Diabetologia.

[3]  I. Cavero-Redondo,et al.  Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis , 2018, Acta Diabetologica.

[4]  P. Hofmann,et al.  Reduction in insulin degludec dosing for multiple exercise sessions improves time spent in euglycaemia in people with type 1 diabetes: A randomized crossover trial , 2018, Diabetes, obesity & metabolism.

[5]  J. Rosenstock,et al.  More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial , 2018, Diabetes Care.

[6]  Ronan Roussel,et al.  Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes. , 2017, Diabetes & metabolism.

[7]  T. Heise,et al.  Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes , 2017, Diabetes, obesity & metabolism.

[8]  D. Dunstan,et al.  Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association , 2016, Diabetes Care.

[9]  M. Matsuhisa,et al.  New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1) , 2016, Diabetes, obesity & metabolism.

[10]  T. Heise,et al.  Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial , 2015, Diabetes, obesity & metabolism.

[11]  A. Mithal,et al.  Clinical use of insulin degludec. , 2015, Diabetes research and clinical practice.

[12]  R. Bergenstal,et al.  New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4) , 2015, Diabetes Care.

[13]  R. Becker,et al.  Continuous Glucose Monitoring During Basal–Bolus Therapy Using Insulin Glargine 300 U mL−1 and Glargine 100 U mL−1 in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study , 2015, Diabetes Therapy.

[14]  T. Heise,et al.  A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance , 2014, Clinical Pharmacokinetics.

[15]  E. Renard,et al.  Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial , 2013, Diabetic medicine : a journal of the British Diabetic Association.

[16]  A. Brazeau,et al.  Barriers to Physical Activity Among Patients With Type 1 Diabetes , 2008, Diabetes Care.

[17]  Thira,et al.  International Society for Pediatric and Adolescent Diabetes (ISPAD) , 2007 .

[18]  P. Cryer,et al.  Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia. , 2003, Diabetes.